TIGLUTIK KIT

PeakSM

riluzole

NDAORALSUSPENSION
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
15

Mechanism of Action

Pharmacologic Class:

Benzothiazole

Clinical Trials (5)

NCT06552260Phase 1Recruiting

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Started Feb 2025
NCT04899921Phase 2Terminated

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Started Jun 2021
NCT04708834Phase 3Terminated

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Started Mar 2021
NCT04641143Phase 3Completed

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Started Dec 2020
NCT06529146N/AActive Not Recruiting

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Started Mar 2019

Loss of Exclusivity

LOE Date
Mar 12, 2029
36 months away
Patent Expiry
Mar 12, 2029

Patent Records (1)

Patent #ExpiryTypeUse Code
8765150
Mar 12, 2029
Product
U-2401